Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, discusses a phase 1b clinical study that evaluated IRAK1/4 inhibition in patients with low-risk myelodysplastic syndromes that are refractory or resistant to prior therapies.
Dr. Garcia-Manero presented information about the study’s design and enrollment process during the 2023 American Society of Clinical Oncology Annual Meeting.